After Mylan uproar, a generic EpiPen could hit the market in 2017 By: MarketWatch August 25, 2016 at 13:15 PM EDT Mylan’s EpiPen monopoly could end in 2017 as the Federal Drug Administration may speed up approval of a generic competitor. Read More >> Related Stocks: Mylan Sanofi-Aventis S.A. ADR Teva Pharmaceutical Industries ADR